BIOSIMULYTICS LIMITED

Biosimulytics Limited delivers a predictive technology platform that makes the development of new medicines far more predictable. By harnessing advanced in‑silico methods, the company helps pharmaceutical and biotech organisations worldwide reduce risk, accelerate timelines and improve the success rate of R & D programmes aimed at bringing novel drug molecules to market.

At the heart of the offering is the CHEMINA™ platform‑as‑a‑service, a modular, automated solution for crystal‑structure prediction (CSP) of small‑molecule APIs. CHEMINA can generate a comprehensive energy‑density landscape from a simple 2‑D chemical diagram, identifying all thermodynamically accessible polymorphs. This enables early‑stage pre‑clinical screening of competing‑form risk, as well as clinical‑stage assessments of patent and manufacturing vulnerabilities, helping clients balance stability, solubility and manufacturability from the outset.

Biosimulytics’ focus on crystal‑form prediction and polymorph control addresses a persistent headache for the pharma industry, where unexpected polymorphs can jeopardise efficacy, safety and regulatory compliance. By combining virtual screening with experimental data, the platform offers a cost‑effective, secure and sustainable route to a “right‑first‑time” approach in drug development.